Sabrina Hoa

Research Scientist, MD MSc FRCPC



  • Rheumatologist, Centre hospitalier de l’Université de Montréal
  • Clinician-scientist, CHUM Research Center
  • Assistant Professor of Medicine, Université de Montréal
  • Université de Montréal Chair in Scleroderma Research


Research Interests

  • Systemic sclerosis (scleroderma)
  • Interstitial lung disease
  • Early risk stratification and treatment

Dr. Sabrina Anh-Tu Hoa is a rheumatologist and clinician-scientist devoted to caring for patients with systemic sclerosis. Her research program aims to develop better risk stratification and treatment strategies early in the disease process in order to decrease the morbidity and mortality burden of systemic sclerosis, with a special focus on interstitial lung disease.

Learn more

Dr. Hoa graduated as a Medical Doctor from McGill University in 2009. She did her Internal Medicine training at McGill University from 2009 to 2012, and pursued her Rheumatology training at Université de Montréal from 2012 to 2015. She then completed a fellowship in systemic sclerosis at the Lady Davis Institute for Medical Research and a Masters of Epidemiology at McGill University from 2015 to 2019. The topic of her Masters thesis was on the role of immunosuppressive drugs in the prevention of incident scleroderma lung disease, and on the role of early treatment in mild forms of scleroderma lung disease. She began her faculty appointment as a Clinical Assistant Professor with the Faculty of Medicine at Université de Montréal in 2019, and works as a rheumatologist and clinician-scientist at the Centre hospitalier de l’Université de Montréal (CHUM) and the CHUM Research Center.

Her current research focuses on early risk stratification and treatment strategies in systemic sclerosis, including in mild stages of interstitial lung disease. She is supported by a Fonds de recherche du Québec – Santé Junior 1 Clinician Research Scholar award since 2022. She also received a CIHR Project Grant to conduct a pilot study to test the feasibility of a randomized controlled trial comparing mycophenolate mofetil to placebo in subclinical interstitial lung disease in systemic sclerosis. She is an active member of the Canadian Scleroderma Research Group (CSRG), acting as PI at the CHUM and as a member of its executive committee, and also contributes to the Scleroderma Patient-centered Intervention Network (SPIN) and the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO).